X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - ZACKS.COM - All Stories - 10/Sep 14:41

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.

Articles similaires

Sorry! Image not available at this time

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

zacks.com - 10/Sep 14:41

FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control...

Sorry! Image not available at this time

DDD Boosts Dental 3D Printing: How Should Investors Play the Stock?

zacks.com - 18:20

3D Systems gains FDA clearance for its advanced jetted denture solution, enhancing durability and efficiency in dental labs for an improved patient...

Sorry! Image not available at this time

3D Systems Expands Orthopedic Surgical Planning Portfolio Receiving FDA Clearance for Key Ankle Indications

healthtechzone.com - 11/Sep 12:30

Sorry! Image not available at this time

THINK Surgical Receives FDA 510(k) Clearance for Zimmer Biomet Persona Knee on TMINI® Miniature Robotic System

healthtechzone.com - 05/Sep 20:00

Sorry! Image not available at this time

THINK Surgical Receives FDA 510(k) Clearance for Zimmer Biomet Persona Knee on TMINI® Miniature Robotic System

healthtechzone.com - 05/Sep 20:00

Sorry! Image not available at this time

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

zacks.com - 12/Sep 15:55

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

Sorry! Image not available at this time

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

zacks.com - 12/Sep 15:55

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

Sorry! Image not available at this time

Alio Launches Calibration and Validation (CAVA) Study to Expand Alio Platform's FDA Clearance Beyond the Vascular Access for Use in a Broader Range of Patients

healthtechzone.com - 12/Sep 18:02

Sorry! Image not available at this time

Alio Launches Calibration and Validation (CAVA) Study to Expand Alio Platform's FDA Clearance Beyond the Vascular Access for Use in a Broader Range of Patients

healthtechzone.com - 12/Sep 18:02

Sorry! Image not available at this time

CVS Stock Gains From Its Birth Control Prescribing Service Launch

zacks.com - 13/Sep 12:25

CVS Health announces that nearly 400 CVS Pharmacy locations in Massachusetts have started offering hormonal contraceptive prescribing services.

Les derniers communiqués